Taiko Pharmaceutical Co (TSE:4574) Long-Term Capital Lease Obligation : 円0 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Taiko Pharmaceutical Co Long-Term Capital Lease Obligation?

Taiko Pharmaceutical Co's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円0 Mil.

Taiko Pharmaceutical Co's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 (円0 Mil) to Dec. 2023 (円22 Mil) but then declined from Dec. 2023 (円22 Mil) to Mar. 2024 (円0 Mil).

Taiko Pharmaceutical Co's annual Long-Term Capital Lease Obligation increased from Mar. 2020 (円52 Mil) to Dec. 2021 (円54 Mil) but then declined from Dec. 2021 (円54 Mil) to Dec. 2022 (円21 Mil).

Taiko Pharmaceutical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Taiko Pharmaceutical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiko Pharmaceutical Co Long-Term Capital Lease Obligation Chart

Taiko Pharmaceutical Co Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Dec21

Dec22

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

15.36

39.20

52.25

54.00

21.00

Taiko Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	22.00	-

Taiko Pharmaceutical Co (TSE:4574) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Taiko Pharmaceutical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Taiko Pharmaceutical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Taiko Pharmaceutical Co (TSE:4574) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taiko Pharmaceutical Co Ltd (TSE:4574) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 34 Third Street, No. 14, Uchihon Suita, Osaka, JPN, 564-0032

Website

http://www.seirogan.co.jp

Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.

Taiko Pharmaceutical Co (TSE:4574) Headlines

No Headlines